10-Q: Cytek Biosciences Reports Revenue Decline, Widened Loss

Cytek Biosciences reported a 5% decrease in total revenue and an increased net loss for the first six months of 2025, alongside identified material weaknesses in internal controls.

Summary

• Total revenue for the six months ended June 30, 2025, decreased by 5% to $87.1 million, down from $91.5 million in the prior year period.
• Product revenue declined by 13% to $59.5 million for the six months ended June 30, 2025, compared to $68.7 million in the same period of 2024, primarily due to lower sales in EMEA and the United States.
• Service revenue increased by 21% to $27.5 million for the six months ended June 30, 2025, up from $22.8 million in the prior year, driven by growth in the installed base and related service contracts.
• Gross profit for the six months ended June 30, 2025, was $44.0 million, a 9.1% decrease from $48.4 million in the same period of 2024, with gross margin declining from 53% to 51%.
• Net loss for the six months ended June 30, 2025, increased to $17.0 million, compared to a net loss of $16.6 million in the prior year period.
• Net cash used in operating activities for the six months ended June 30, 2025, was $0.017 million, a significant decrease from $10.161 million provided by operating activities in the same period of 2024.
• General and administrative expenses increased by 14% to $26.4 million for the six months ended June 30, 2025, primarily due to ongoing patent litigation expenses.
• Research and development expenses decreased by 6% to $18.6 million for the six months ended June 30, 2025, mainly due to lower headcount and engineering expenses.
• The company repurchased 3,292,588 shares of common stock for approximately $15.1 million during the six months ended June 30, 2025, under a $50 million program expiring December 31, 2025, with $35.0 million remaining authorized.
• Material weaknesses in internal control over financial reporting were identified for the year ended December 31, 2024, related to control environment and control activities, with remediation efforts ongoing.

Sentiment

Score: 3

Explanation: The company's financial performance shows a clear decline in revenue and an increased net loss, coupled with a significant shift to negative cash flow from operations. The identified material weaknesses in internal controls and ongoing patent litigation add substantial risk and uncertainty. While service revenue growth is positive, it does not offset the overall negative trends. The need for potential future capital raises further underscores financial pressure.

Positives

• Service revenue increased by 21% for the six months ended June 30, 2025, indicating continued growth in the installed base and service contracts.
• Research and development expenses decreased by 6% for the six months ended June 30, 2025, due to lower headcount and engineering expenses, potentially indicating cost efficiency.
• Other income, net, significantly increased to $7.2 million for the six months ended June 30, 2025, primarily driven by foreign exchange gains and reclassification of investment income.

Negatives

• Total revenue decreased by 5% for the six months ended June 30, 2025, primarily due to lower product sales.
• Product revenue declined by 13% for the six months ended June 30, 2025, with notable decreases in EMEA and the United States.
• Net loss increased to $17.0 million for the six months ended June 30, 2025, indicating a worsening financial performance.
• Gross profit decreased by 9.1% and gross margin declined from 53% to 51% for the six months ended June 30, 2025, reflecting higher cost of sales relative to revenue.
• Net cash used in operating activities was $0.017 million for the six months ended June 30, 2025, a significant shift from positive cash flow in the prior year, indicating increased cash burn from core operations.
• General and administrative expenses increased by 14% due to ongoing patent litigation expenses.

Risks

• Limited operating history and experience in marketing and selling products, making future performance difficult to predict.
• High dependence on a limited number of product offerings (Cytek Aurora, Northern Lights, Aurora CS systems), making revenue prone to quarterly fluctuations and sales cycle length.
• Reliance on single and sole source suppliers for key components, posing risks of supply interruptions and increased costs.
• Inability to accurately forecast customer demand and manage inventory, potentially leading to shortages or excesses.
• Exposure to business, regulatory, political, operational, financial, and economic risks associated with international operations and expansion, including tariffs and export controls (e.g., new U.S. license requirements impacting exports to China).
• Limited experience manufacturing products, with potential for quality issues, defects, or recalls as production scales.
• Future success is dependent on increasing penetration in existing markets and expanding into adjacent markets, which may not materialize as expected.
• Business is significantly dependent on research and development spending by academic and government-owned institutions, which could be reduced.
• Reliance on distributors for sales in certain geographies, with risks if they do not perform adequately or effectively.
• Highly competitive market for cell analysis technologies and life sciences tools, potentially limiting revenue growth and profitability.
• New product development is lengthy and complex, with no assurance of timely commercialization or market acceptance.
• Potential for product defects or reliability issues, leading to increased costs, reduced net sales, and reputational harm.
• Risks associated with potential acquisitions, joint ventures, or investments in other companies or technologies, including integration difficulties and unknown liabilities.
• Shipping is a critical part of the business, subject to disruptions, increased costs, and potential damage or loss in transit.
• Inability to successfully expand commercial operations by hiring and retaining qualified sales, technical, and support staff.
• Failure to expand or leverage peer-reviewed articles or increase brand awareness could adversely affect demand.
• Difficulties in managing organizational growth, potentially straining infrastructure and leading to inefficiencies.
• Identified material weaknesses in internal control over financial reporting, which if not remediated, could impact financial reporting accuracy and timeliness.
• Need to raise additional capital to fund operations and expansion, which may not be available on acceptable terms or could dilute existing stockholders.
• Operating results may fluctuate significantly due to various factors, making future results difficult to predict.
• Products may become subject to more onerous FDA or other regulatory agency regulations, increasing costs and delaying sales.
• Ongoing regulatory obligations and review, with potential penalties for non-compliance.
• Risk of product recalls, voluntarily or mandated, due to safety issues or defects.
• Misuse or off-label use of products could harm reputation or lead to product liability suits and FDA sanctions.
• Stringent and changing U.S. and foreign data privacy and security laws, regulations, and industry standards, with potential for investigations, fines, litigation, and business disruption.
• Exposure to U.S. and foreign anti-corruption and anti-money laundering laws, with potential for criminal liability and other serious consequences for violations.
• Potential for substantial liabilities from product liability claims exceeding resources.
• Litigation and other legal proceedings, including ongoing patent infringement lawsuits, could harm business and divert management attention.
• Inability to obtain and maintain patent or other intellectual property protection, or challenges to existing IP, could allow competitors to commercialize similar products.
• Concentration of common stock ownership among executive officers, directors, and principal stockholders may prevent new investors from influencing significant corporate decisions.
• Changes in U.S. patent law could diminish the value of patents, impairing ability to protect products.
• Limited foreign intellectual property rights outside the U.S., selected EU countries, Japan, and China, making global protection difficult.
• Claims that employees, consultants, or advisors have wrongfully used or disclosed trade secrets of former employers.
• Failure to protect the confidentiality of trade secrets could harm business and competitive position.
• Failure of key information technology systems, processes, or sites could adversely affect business.
• Use of open source software could compromise ability to offer services and lead to litigation.
• Changes in effective tax rate or tax liability due to various factors, including changes in tax laws and audits.
• Uncertainties in the tax system in countries of operation could adversely affect financial condition.

Future Outlook

The company anticipates continued significant cash expenditure for research and development, commercialization of new products, and market expansion. Future capital requirements depend on revenue, R&D efforts, capital expenditures for facilities and manufacturing, and sales/marketing expansion. The company believes existing cash and anticipated cash flows will be sufficient for at least the next 12 months. The impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on deferred tax assets and liabilities will be reflected in the interim financial statements for the three and nine months ending September 30, 2025.

Management Comments

• Total revenue for the three and six months ended June 30, 2025, decreased compared to the prior year due to lower product revenue resulting from lower product sales in the United States to academic and government customers and in EMEA to biotechnology and pharmaceutical customers.
• The increase in service revenue was primarily due to continued growth of the installed base with the related increase in service contracts and maintenance activity.
• The decrease in research and development expenses was primarily due to lower headcount and engineering expenses.
• The increase in general and administrative expenses was primarily due to ongoing patent litigation expenses incurred in 2025.
• The decrease in interest income was the result of lower average balance of cash and cash equivalents and short-term investments as compared to the prior year due to the transfer of funds from cash accounts to marketable securities accounts, the income from which is classified as investment income, included in Other income, net, rather than interest income, and a lower interest rate environment.
• The increase in other income was primarily driven by an increase in realized and unrealized foreign exchange gains and movement of cash from interest bearing accounts to investment accounts.
• We expect our expenses will increase substantially in connection with our ongoing activities, as we attract, hire and retain qualified personnel; invest in processes, commercial infrastructure and supporting functions to scale our business and introduce new products and services; support our research and development efforts; continue to expand geographically; protect and defend our intellectual property; and make strategic investments in complementary businesses, services, products or technologies.
• We believe our existing cash and cash equivalents and anticipated cash flows from operations will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.

Industry Context

The company operates in the highly competitive cell analysis and life sciences tools markets, facing established and early-stage competitors. The industry is characterized by significant technological advancements and evolving standards. The company's performance is impacted by global macroeconomic conditions, inflation, interest rates, and geopolitical tensions, which affect customer fundraising, sales cycles, and trade policies. Changes in government funding for academic research (e.g., NIH policy) also directly influence demand from a significant customer segment.

Comparison to Industry Standards

• The market for cell analysis technologies and life sciences tools, including flow cytometry, is highly competitive. Key competitors mentioned include Agilent Technologies, Beckman Coulter (Danaher Corporation), Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Standard BioTools Inc., Miltenyi Biotec, Sony Biotechnology (Sony Corporation), and Thermo Fisher Scientific.
• The company's products, such as the Cytek Aurora, Northern Lights, and Aurora CS systems, compete directly with offerings from these established players, which often have longer operating histories, larger customer bases, and greater financial resources.
• The company's strategy to expand into clinical markets in the United States requires FDA clearance (510(k) or PMA), a process that competitors with existing clinical products may have already navigated or have more experience with.
• The company's reliance on single/sole source suppliers for key components, such as certain lasers and semiconductors, is a common industry challenge but can be a competitive disadvantage if not managed effectively compared to larger competitors with more diversified supply chains.
• The ongoing patent litigation with Beckman Coulter highlights the intense intellectual property landscape within the flow cytometry industry, where disputes are common among major players.

Corporate Governance

Legal Proceedings

• Beckman Coulter, Inc. filed a lawsuit on August 14, 2024, alleging infringement of U.S. Patent Nos. 10,330,582 and 11,703,443 by Cytek's Aurora flow cytometers, Aurora CS cell sorters, and Northern Lights and Northern Lights-CLC products.
• The company filed a counterclaim against Beckman Coulter for false marking on October 7, 2024.
• Beckman Coulter filed a first amended complaint on January 9, 2025, alleging infringement of additional U.S. Patent Nos. 12,174,106 and 12,174,107.
• The company filed an answer to the first amended complaint with a counterclaim for false patent marking on February 6, 2025.
• A claim construction hearing is scheduled for August 21, 2025, briefing on dispositive motions for March and April 2026, and a trial for August 17, 2026.
• The company intends to vigorously defend itself and pursue its counterclaims.

Stakeholder Impact

• **Shareholders:** Experience dilution risk from potential future capital raises, and negative impact on stock price due to declining revenue, increased losses, and internal control weaknesses. Share repurchase program aims to return capital and minimize dilution, but its effectiveness is limited by overall performance.
• **Employees:** Impacted by lower headcount in R&D, but also by efforts to augment workforce in accounting and IT for remediation of internal control weaknesses. Ongoing patent litigation may divert attention and resources.
• **Customers:** May experience longer sales cycles due to difficult fundraising environment for small companies and high interest rates among pharmaceutical and biotech customers. Potential for product defects or reliability issues could impact customer satisfaction, though the company provides warranties.
• **Suppliers:** The company's reliance on single/sole source suppliers creates risk for both parties if supply is interrupted or terms change. The manufacturing transition to Singapore may impact existing supplier relationships in Seattle.
• **Creditors:** The company has taken on new loans and lines of credit, increasing debt obligations, but states existing cash and anticipated cash flows should be sufficient for the next 12 months.

Next Steps

• Transition manufacturing operations from Seattle, Washington, to Singapore by the end of fiscal year 2025 to optimize efficiency and reduce costs.
• Reflect the impact of the One Big Beautiful Bill Act (OBBBA) in the interim financial statements for the three and nine months ending September 30, 2025.
• Continue to invest in research and development efforts to develop new and complementary instruments, reagents, and software.
• Continue to invest in commercial infrastructure, including hiring additional sales, marketing, and business development personnel globally.
• Pursue required regulatory approvals for clinical use of Cytek Aurora and Northern Lights systems in the United States and other countries.
• Remediate identified material weaknesses in internal control over financial reporting by augmenting workforce, revising control design, expanding education/training, strengthening supervisory reviews, and focusing on control execution and monitoring.

Key Dates

Recommendation

The company's financial performance for the six months ended June 30, 2025, shows concerning trends, including a 5% decline in total revenue, a 13% drop in product revenue, and an increased net loss. Critically, net cash flow from operating activities turned negative, indicating a significant cash burn from core operations. The identified material weaknesses in internal control over financial reporting raise serious governance and financial reporting reliability concerns. Furthermore, the ongoing, complex patent litigation with Beckman Coulter introduces substantial legal and financial uncertainty, with a trial not expected until August 2026. While service revenue growth is a positive, it is insufficient to offset the broader negative trends. Given the deteriorating financial metrics, significant internal control issues, and unresolved litigation, a seasoned investor would likely view this filing as a strong signal to reduce exposure or exit the position.

Keywords

Cell Analysis, Flow Cytometry, Biomedical Research, Clinical Applications, FSP Technology, Cytek Aurora, Northern Lights, Aurora CS, Biotechnology, Pharmaceutical, Academic Research, SEC Filing, 10-Q, Financial Results, Revenue, Net Loss, Internal Controls, Patent Litigation, Share Repurchase